Methylphenidate induces lipid and protein damage in prefrontal cortex, but not in cerebellum, striatum and hippocampus of juvenile rats

Metabolic Brain Disease

Volumn 27, Issue 4, 2012, Pages 605-612

  Schmitz, Felipe ^a   Scherer, Emilene B S ^a   Machado, Fernanda R ^a   Da Cunha, Aline A ^a   Tagliari, Bárbara ^a   Netto, Carlos A ^a   Wyse, Angela T S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Encephalic structures; Juvenile rats; Methylphenidate; Oxidative status

Indexed keywords

CATALASE; METHYLPHENIDATE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; HIPPOCAMPUS; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; RAT;

ANIMALS; ANTIOXIDANTS; CATALASE; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBELLUM; FLUORESCEINS; GLUTATHIONE PEROXIDASE; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; METHYLPHENIDATE; NEOSTRIATUM; NITRIC OXIDE; OXIDATIVE STRESS; PREFRONTAL CORTEX; RATS; RATS, WISTAR; REACTIVE NITROGEN SPECIES; SULFHYDRYL COMPOUNDS; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84871428143     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-012-9335-5     Document Type: Article

References (80)

1. Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121-126
2. Aksenov MY, Markesbery WR (2001) Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neurosci Lett 302:141-145
3. Andersen SL (2004) Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 27:3-18
4. Andreazza AC, Frey BN, Valvassori SS, Zanotto C, Gomes KM, Comim CM et al (2007) DNA damage in rats after treatment with methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 31:1282-1288
5. Arnsten AF (2009) Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 23:33-41
6. Aylward EH, Reiss AL, Reader MJ, Singer HS, Brown JE, Denckla MB (1996) Basal ganglia volumes in children with attentiondeficit hyperactivity disorder. J Child Neurol 11:112-115
7. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervick B (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 324:25-28
8. Benes FM (1998) Brain development, VII. Human brain growth spans decades. Am J Psychiatry 155:1489
9. Biederman J, Mick E, Faraone SV (2000) Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157:816-818
10. Biederman J, Spencer T, Wilens T (2004) Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 7:77-97
11. Bowler RP, Crapo JD (2002) Oxidative stress in airways: is there a role for extracellular superoxide dismutase? Am J Respir Crit Care Med 166:38-43
12. Brown MF, Yamamoto S (2003) Effects of amphetamine on mitochondrial function: role of free radicals and oxidative stress. Pharmacol & Terap 99:45-53
13. Castellanos FX (1997) Toward a pathophysiology of attention-deficit/ hyperactivity disorder. Clin Pediatr 36:381-393
14. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DP et al (1996) Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53:607-616
15. Challman TD, Lipsky JJ (2000) Methylphenidate: its pharmacology and uses. Mayo Clin Proc 75:711-721
16. Chase TD, Brown RE, Carrey N, Wilkinson M (2003) Daily methylphenidate administration attenuates c-fos expression in the striatum of prepubertal rats. Neuroreport 14:769-772
17. Cooke MS, Evans MD, Dove R, Rozalski R, Gackowski D, Siomek A et al (2005) DNA repair is responsible for the presence of oxidatively damaged DNA lesions in urine. Mutat Res 574:58-66
18. Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis. Biochem Biophys Res Commun 331:761-777
19. Dinn WM, Robbins NC, Harris CL (2001) Adult attention-deficit/ hyperactivity disorder: neuropsychological and clinical presentation. Brain Cogn 46:114-121
20. DoughertyDD,BonabAA,SpencerTJ,RauchSL,MadrasBK,Fischaman AJ (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354:2132-2133
21. Drouin C, Page M, Waterhouse B (2006) Methylphenidate enhances noradrenergic transmission and suppresses mid-And long-latency sensory responses in the primary somatosensory cortex of awake rats. J Neurophysiol 96:622-632
22. Fagundes AO, Rezin GT, Zanette F, Grandi E, Assis LC, Dal-Pizzol F et al (2007) Chronic administration of methylphenidate activates mitochondrial respiratory chain in brain of young rats. Int J Dev Neurosci 25:47-51
23. Faraone SV (2004) Genetics of adult attention deficit hyperactivity disorder. In: Spencer T (ed) Psychiatric clinics of North America. PA. Sauders Press, Philadelphia, pp 3030-321
24. Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104-113
25. Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M (2004) Effect of antioxidant N-Acetyl-cysteine on behavioral changes and neurotoxicity in rats after administration of metahnphetamine. Brain Res 1016:90-95
26. Garland EJ (1998) Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choice and caveats. J Psychopharmacology 12:385-395
27. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D et al (2000) Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther 295:51-57
28. Goldman LS, Genel M, Bezman RJ, Slanetz PJ (1998) Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 279:1100-1107
29. Goldman-Rakic PS, Muly EC, Williams GV (2000) D(1) receptors in prefrontal cell and circuits. Brain Res Brain Res Rev 31:295-301
30. Gomes KM, Petronilho FC, Mantovani M, Garbelotto T, Boeck CR, Dal-Pizzol F et al (2008) Antioxidant enzyme activities following acute and chronic methylphenidate treatment in young rats. Neurochem Res 33:1024-1027
31. Gomes KM, Inácio CG, Valvassori SS, Réus GZ, Boeck CR, Dal-Pizzol F et al (2009) Superoxide production after acute and chronic treatment with methylphenidate in young and adult rats. Neurosci Lett 465:95-98
32. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126:131-138
33. Greenhill LL (2001) Clinical effects of stimulant medication in attention-deficti/hyperactivity disorder (ADHD). In: Solanto MV, Arnsten AFT, Castellanos FX (eds) Stimulant drugs and ADHD: basic and clinical neuroscience. Oxford University Press, New York, pp 31-71
34. Gutteridge JMC (2001) Free Radicals in Biology and Medicine, 4th edn. Oxford University Press Inc, New York, p 851
35. Halliwell B, Gutteridge JMC (2007) Free Radicals in Biology and Medicine, 4th edn. Oxford University Press, New York, p 851
36. Husson I, Mesplès B, Medja F, Leroux P, Kosofsky B, Gressens P (2004) Methylphenidate and Mk-801, an N-methyl-D-Aspartate receptor antagonist: shared biological properties. Neuroscience 125:163-170
37. Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, Byrns RE (1993) Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-Arginine. Proc Natl Acad Sci USA 90:8103-8107
38. Ikai Y, Takada M, Shinonaga Y, Mizuno N (1992) Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei. Neuroscience 51:719-728
39. Ikai Y, Takada M, Mizuno N (1994) Single neurons in the ventral tegmental area that project to both the central and cerebellar cortical areas by way of axon collaterals. Neuroscience 61:925-934
40. Issy AC, Salum C, Del Bel EA (2009) Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibiton in Swiss mice. Behav Brain Res 205:475-481
41. Itzhak Y, Ali SF (2006) Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. Pharmacol Ther 109:246-262
42. Kirby K, Rutman LE, Bernstein H (2002) Attention-deficit/hiperactivity disorder: a therapeutic update. Curr Opin Pediatr 14:236-246
43. Kuczenski R, Segal DS (2001) Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 296:876-883
44. Kuczenski R, Segal DS (2002) Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22:7264-7271
45. LeBel CP, Ali SF, McKee M, Bondy SC (1990) Organometal-induced increases in oxygen reactive species: the potential of 2′,7′- dichlorofluorescin diacetate as an index of neurotoxic damage. Toxicol Appl Pharmacol 104:17-24
46. Lou H (1996) Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): significance of prematurity and perinatal hypoxichaemodynamic encephalopathy. Acta Paediatr 85:1266-1271
47. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
48. Machado A (2004) Neuroanatomia Funcional, 2nd edn. Atheneu, São Paulo, pp 1993-2000
49. Marklund SL (1985) Pyrogallol autoxidation. In: Handbook for Oxygen Radical Research. CRC Press, Boca Raton, pp 243-247
50. Martins MR, Reinke A, Petronilho FC, Gomes KM, Dal-Pizzol F, Quevedo J (2006) Methylphenidate treatment induces oxidative stress in young rat brain. Brain Res 1078:189-197
51. Matés JM, Pérez-Gómez C, Núñez de Castro I (1999) Antioxidant enzymes and human diseases. Clin Biochem 32:595-603
52. Melchitzky DS, Lewis DA (2000) Tyrosine hydroxylase-And dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular-And laminar-specific dopamine innervation. Neuropsychopharmacology 22:466-472
53. Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV (2002) Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr 23:16-22
54. Miller KJ, Castellanos FX (1998) Attention deficit/hyperactivity disorders. Pediatr Rev 19:373-384
55. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358
56. Radi R, Cassiana A, Hodara R, Quijano C, Castro L (2002) Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 33:1451-1464
57. Rice D, Barone S Jr (2000) Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108:511-533
58. Rowland SA, Lesesne CA, Abramowitz AJ (2002) The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev 8:162-170
59. Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SC, Simmons A et al (1999) Hypofrontality in attention deficit hyperactivity during higher-order motor control: a study with functional MRI. Am J Psychiatry 156:891-896
60. Rubia K, Taylor E, Smith AB, Oksanen H, Overmeyer S, Newman S (2001) Neuropsychological analyses of impulsiveness in childhood hyperactivity. Br J Psychiatry 179:138-143
61. Safer DJ, Allen RP (1989) Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children. J Pediatr 115:1003-1008
62. Sarkar A, Bhaduri A (2001) Black tea is a powerful chemopreventor of reactive oxygen and nitrogen species: comparison with its individual catechin constituents and green tea. Biochem Biophys Res Commun 284:173-178
63. Scherer EB, Matté C, Ferreira AG, Gomes KM, Comim CM, Mattos C et al (2009) Methylphenidate treatment increases Na(+), K (+)-ATPase activity in the cerebrum of young and adult rats. J Neural Transm 116:1681-1687
64. Scherer EB, da Cunha MJ, Matté C, Schmitz F, Netto CA, Wyse AT (2010) Methylphenidate affects memory, brain-derived 612 Metab Brain Dis (2012) 27:605-612
65. neurotrophic factor immunocontent and brain acetylcholinesterase activity in the rat. Neurobiol Learn Mem 94:247-253
66. Schmitz F, Scherer EB, da Cunha MJ, da Cunha AA, Lima DD, Delwing D et al (2012) Chronic methylphenidate administration alters antioxidant defenses and butyrylcholinesterase activity in blood of juvenile rats. Mol Cell Biochem 361:281-288
67. Schweri MM, Skolnick P, Rafferty MF, Rice KC, Janowsky AJ, Paul SM (1985) [3H] Treo-(+/-)-methylphenidate binding to 3,4-dihidroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J Neurochem 45:1062-1070
68. Sunohara GA, Malone MA, Rovet J, Humphries T, Roberts W, Taylor MJ (1999) Effect of methylphenidate on attention in children with attention deficit hyperactivity disorder (ADHD): ERP evidence. Neuropsychopharmacology 21:218-228
69. Swanson JM, Volkow ND (2002) Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res 130:73-78
70. Swanson J, Castellanos FX, Murias M, LaHoste G, Kennedy J (1998) Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol 8:263-271
71. Taylor FB, Russo J (2001) Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 21:223-228
72. Vaidya C, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH et al (1998) Selective effects methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci USA 95:14494-14499
73. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1-40
74. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS et al (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325-1331
75. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382
76. Volkow ND, Wang GJ, Fowler JS, Ding YS (2005) Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1410-1415
77. Wendel A (1981) Glutathione peroxidase. Methods Enzymol 77:325-333
78. Wigal T, Swanson JM, Regino R, Lerner MA, Soliman I, Steinhoff K (1999) Stimulant medications for the treatment of ADHD: efficacy and limitations. Ment Retard Dev Disabil Res Rev 5:215-224
79. Wilens TE, Biederman J, Spencer TJ (2002) Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med 53:113-131
80. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F (2000) Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025-1030